SCHEMBL26919191

SCHEMBL26919191

O=C(O)OC1[C@H]2CN(c3ccc(Br)cn3)C[C@@H]12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 1/20 0.45
▸ AKR1C3 P42330 1/20 0.44
▸ PPARG P37231 1/20 0.40
▸ PPARD Q03181 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ PDE10A Q9Y233 1/20 0.40
▸ GRIN2D O15399 1/20 0.39
▸ GRIN3B O60391 1/20 0.39
▸ GRIN1 Q05586 1/20 0.39
▸ GRIN2A Q12879 1/20 0.39
▸ GRIN2B Q13224 1/20 0.39
▸ GRIN2C Q14957 1/20 0.39
▸ GRIN3A Q8TCU5 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ PANK3 Q9H999 1/20 0.38
▸ CHRM4 P08173 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.34
▸ HRH3 Q9Y5N1 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20474698 0.78 AKR1C3 (0.49) ACACBAKR1C3PPARGPPARDPPARA
SCHEMBL29032826 0.76 ACACB (0.43) ACACBAKR1C3PPARGPPARDPPARA
SCHEMBL29749107 0.74 ACACB (0.44) ACACBAKR1C3PPARGPPARDPPARA
SCHEMBL30283050 0.74 PDE10A (0.50) ACACBAKR1C3PPARGPPARDPPARA
SCHEMBL13547453 0.74 PDE10A (0.50) ACACBAKR1C3PPARGPPARDPPARA
SCHEMBL26919005 0.74 PDE10A (0.51) ACACBAKR1C3PPARGPPARDPPARA
SCHEMBL26919007 0.74 PDE10A (0.51) ACACBAKR1C3PPARGPPARDPPARA
SCHEMBL29749067 0.74 PDE10A (0.51) ACACBAKR1C3PPARGPPARDPPARA
SCHEMBL21812409 0.74 AKR1C3 (0.48) ACACBAKR1C3PPARGPPARDPPARA
SCHEMBL25404700 0.73 AKR1C3 (0.45) ACACBAKR1C3PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174674-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) 2024-05-30 — — US disclosed
EP-4289428-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF Applied Pharmaceutical Science, Inc. (CN) 2023-12-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174674-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF RET, WEE1, JAK2 ACACB 4590/4885AKR1C3 2543/4885PPARG 2965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback